Evidence map›Paper›PMID 36535990›Full record

ArticleScientific reports2022

Comparability of automated drusen volume measurements in age-related macular degeneration: a MACUSTAR study report.

Davide Garzone, Jan Henrik Terheyden, Olivier Morelle, Maximilian W M Wintergerst, Marlene Saßmannshausen, Steffen Schmitz-Valckenberg, Maximilian Pfau, Sarah Thiele, Stephen Poor, Sergio Leal and 3 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03349801 (Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03349801 active not recruitingnot on this map

Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)

TypeobservationalSponsorFrank G. HolzRan2018 to 2026Enrolled718ConditionsAge Related Macular Degeneration (AMD)ArmsNo intervention
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. RPE Curvature Can Screen for Early and Intermediate AMD.Investigative ophthalmology & visual science · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 20 institutions in 9 countries.

Davide GarzoneDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Jan Henrik TerheydenDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Olivier MorelleDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Maximilian W M WintergerstDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Marlene SaßmannshausenDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Steffen Schmitz-ValckenbergDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Maximilian PfauDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Sarah ThieleDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Stephen PoorOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Sergio LealBayer Pharmaceuticals, Berlin, Germany.
Frank G HolzDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany.
Robert P FingerDepartment of Ophthalmology, University Hospital Bonn, Ernst-Abbe Str. 2, 53127, Bonn, Germany. robert.finger@ukbonn.de.
MACUSTAR Consortium
University Hospital Bonn · DEAssociation for Innovation and Biomedical Research on Light and Image · PTNovartis (Switzerland) · CHCity, University of London · GBBayer (Germany) · DEEuropean Clinical Research Infrastructure Network · FRSorbonne Université · FRUniversity College London · GBUniversity of Sheffield · GBFondazione G.B. Bietti · ITHospital de São João · PTInstitut für Medizinische Biometrie, Informatik und Epidemiologie · DELudwig-Maximilians-Universität München · DELuigi Sacco Hospital · ITRadboud University Medical Center · NLSTZ eyetrial · DEUniversität Ulm · DEUniversity Hospital Cologne · DEUniversity of Bonn · DECarl Zeiss (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drusen are hallmarks of early and intermediate age-related macular degeneration (AMD) but their quantification remains a challenge. We compared automated drusen volume measurements between different OCT devices. We included 380 eyes from 200 individuals with bilateral intermediate (iAMD, n = 126), early (eAMD, n = 25) or no AMD (n = 49) from the MACUSTAR study. We assessed OCT scans from Cirrus (200 × 200 macular cube, 6 × 6 mm; Zeiss Meditec, CA) and Spectralis (20° × 20°, 25 B-scans; 30° × 25°, 241 B-scans; Heidelberg Engineering, Germany) devices. Sensitivity and specificity for drusen detection and differences between modalities were assessed with intra-class correlation coefficients (ICCs) and mean difference in a 5 mm diameter fovea-centered circle. Specificity was > 90% in the three modalities. In eAMD, we observed highest sensitivity in the denser Spectralis scan (68.1). The two different Spectralis modalities showed a significantly higher agreement in quantifying drusen volume in iAMD (ICC 0.993 [0.991-0.994]) than the dense Spectralis with Cirrus scan (ICC 0.807 [0.757-0.847]). Formulae for drusen volume conversion in iAMD between the two devices are provided. Automated drusen volume measures are not interchangeable between devices and softwares and need to be interpreted with the used imaging devices and software in mind. Accounting for systematic difference between methods increases comparability and conversion formulae are provided. Less dense scans did not affect drusen volume measurements in iAMD but decreased sensitivity for medium drusen in eAMD.Trial registration: ClinicalTrials.gov NCT03349801. Registered on 22 November 2017.

Indexed as

Macular DegenerationFovea CentralisHumansRetinaSoftwareTomography, Optical Coherence

Identifiers

PMID36535990
PMCPMC9763254
OpenAlexW4312094133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.